Titre :

Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study.

Auteur(s) :

Arab, J. P. [Auteur]
Díaz, L. A. [Auteur]
Baeza, N. [Auteur]
Idalsoaga, F. [Auteur]
Fuentes-López, E. [Auteur]
Arnold, J. [Auteur]
Ramírez, C. A. [Auteur]
Morales-Arraez, D. [Auteur]
Ventura-Cots, M. [Auteur]
Alvarado-Tapias, E. [Auteur]
Zhang, W. [Auteur]
Clark, V. [Auteur]
Simonetto, D. [Auteur]
Ahn, J. C. [Auteur]
Buryska, S. [Auteur]
Mehta, T. I. [Auteur]
Stefanescu, H. [Auteur]
Horhat, A. [Auteur]
Bumbu, A. [Auteur]
Dunn, W. [Auteur]
Attar, B. [Auteur]
Agrawal, R. [Auteur]
Haque, Z. S. [Auteur]
Majeed, M. [Auteur]
Cabezas, J. [Auteur]
García-Carrera, I. [Auteur]
Parker, R. [Auteur]
Cuyàs, B. [Auteur]
Poca, M. [Auteur]
Soriano, G. [Auteur]
Sarin, S. K. [Auteur]
Maiwall, R. [Auteur]
Jalal, P. K. [Auteur]
Abdulsada, S. [Auteur]
Higuera-De La Tijera, M. F. [Auteur]
Kulkarni, A. V. [Auteur]
Rao, P. N. [Auteur]
Salazar, P. G. [Auteur]
Skladaný, L. [Auteur]
Bystrianska, N. [Auteur]
Prado, V. [Auteur]
Clemente-Sanchez, A. [Auteur]
Rincón, D. [Auteur]
Haider, T. [Auteur]
Chacko, K. R. [Auteur]
Cairo, F. [Auteur]
De Sousa Coelho, M. [Auteur]
Romero, G. A. [Auteur]
Pollarsky, F. D. [Auteur]
Restrepo, J. C. [Auteur]
Castro-Sanchez, S. [Auteur]
Toro, L. G. [Auteur]
Yaquich, P. [Auteur]
Mendizabal, M. [Auteur]
Garrido, M. L. [Auteur]
Narvaez, A. [Auteur]
Bessone, F. [Auteur]
Marcelo, J. S. [Auteur]
Piombino, D. [Auteur]
Dirchwolf, M. [Auteur]
Arancibia, J. P. [Auteur]
Altamirano, J. [Auteur]
Kim, W. [Auteur]
Araujo, R. C. [Auteur]
Rojo, A. D. [Auteur]
Vargas, V. [Auteur]
Rautou, Pierre-Emmanuel [Auteur]
Hôpital Beaujon [AP-HP]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Issoufaly, Tazime [Auteur]
Service d’Hépatologie [Hôpital Beaujon]
Centre de recherche sur l'Inflammation [CRI (UMR_S_1149 / ERL_8252 / U1149)]
Zamarripa, F. [Auteur]
Torre, A. [Auteur]
Lucey, M. R. [Auteur]
Mathurin, Philippe [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Louvet, Alexandre [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
García-Tsao, G. [Auteur]
González, J. A. [Auteur]
Verna, E. [Auteur]
Brown, R. S. [Auteur]
Roblero, J. P. [Auteur]
Abraldes, J. G. [Auteur]
Arrese, M. [Auteur]
Shah, V. H. [Auteur]
Kamath, P. S. [Auteur]
Singal, A. K. [Auteur]
Bataller, R. [Auteur]

Titre de la revue :

Journal of Hepatology

Nom court de la revue :

J Hepatol

Date de publication :

2021-06-26

ISSN :

1600-0641

Mot(s)-clé(s) en anglais :

alcohol
alcoholic hepatitis
alcohol-associated liver disease
alcoholic liver disease
cirrhosis
steroids
corticosteroids
MELD
Maddrey discriminant function

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background & Aims Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too ...
Lire la suite >Background & Aims Corticosteroids are the only effective therapy for severe alcohol-associated hepatitis (AH), defined by a model for end-stage liver disease (MELD) score >20. However, there are patients who may be too sick to benefit from therapy. Herein, we aimed to identify the range of MELD scores within which steroids are effective for AH. Methods We performed a retrospective, international multicenter cohort study across 4 continents, including 3,380 adults with a clinical and/or histological diagnosis of AH. The main outcome was mortality at 30 days. We used a discrete-time survival analysis model, and MELD cut-offs were established using the transform-the-endpoints method. Results In our cohort, median age was 49 (40–56) years, 76.5% were male, and 79% had underlying cirrhosis. Median MELD at admission was 24 (19–29). Survival was 88% (87–89) at 30 days, 77% (76–78) at 90 days, and 72% (72–74) at 180 days. A total of 1,225 patients received corticosteroids. In an adjusted-survival-model, corticosteroid use decreased 30-day mortality by 41% (hazard ratio [HR] 0.59; 0.47–0.74; p <0.001). Steroids only improved survival in patients with MELD scores between 21 (HR 0.61; 0.39–0.95; p = 0.027) and 51 (HR 0.72; 0.52–0.99; p = 0.041). The maximum effect of corticosteroid treatment (21–30% survival benefit) was observed with MELD scores between 25 (HR 0.58; 0.42–0.77; p <0.001) and 39 (HR 0.57; 0.41–0.79; p <0.001). No corticosteroid benefit was seen in patients with MELD >51. The type of corticosteroids used (prednisone, prednisolone, or methylprednisolone) was not associated with survival benefit (p = 0.247). Conclusion Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39. Lay summary Alcohol-associated hepatitis is a condition where the liver is severely inflamed as a result of excess alcohol use. It is associated with high mortality and it is not clear whether the most commonly used treatments (corticosteroids) are effective, particularly in patients with very severe liver disease. In this worldwide study, the use of corticosteroids was associated with increased 30-day, but not 90- or 180-day, survival. The maximal benefit was observed in patients with an MELD score (a marker of severity of liver disease; higher scores signify worse disease) between 25-39. However, this benefit was lost in patients with the most severe liver disease (MELD score higher than 51).Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T06:34:11Z
2024-03-01T14:44:01Z